Download MendeleySynthesis, structure-activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis.
Ghazy, E., Heimburg, T., Lancelot, J., Zeyen, P., Schmidtkunz, K., Truhn, A., Darwish, S., Simoben, C.V., Shaik, T.B., Erdmann, F., Schmidt, M., Robaa, D., Romier, C., Jung, M., Pierce, R., Sippl, W.(2021) Eur J Med Chem 225: 113745-113745
- PubMed: 34392190
- DOI: https://doi.org/10.1016/j.ejmech.2021.113745
- Primary Citation of Related Structures:
7P3S - PubMed Abstract:
Schistosomiasis is a major neglected parasitic disease that affects more than 265 million people worldwide and for which the control strategy consists of mass treatment with the only available drug, praziquantel. In this study, we chemically optimized our previously reported benzhydroxamate-based inhibitors of Schistosoma mansoni histone deacetylase 8 (smHDAC8). Crystallographic analysis provided insights into the inhibition mode of smHDAC8 activity by the highly potent inhibitor 5o. Structure-based optimization of the novel inhibitors was carried out using the available crystal structures as well as docking studies on smHDAC8. The compounds were evaluated in screens for inhibitory activity against schistosome and human HDACs (hHDAC). The in vitro and docking results were used for detailed structure activity relationships. The synthesized compounds were further investigated for their lethality against the schistosome larval stage using a fluorescence-based assay. The most promising inhibitor 5o showed significant dose-dependent killing of the schistosome larvae and markedly impaired egg laying of adult worm pairs maintained in culture.
Organizational Affiliation:
Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, 06120, Halle/Saale, Germany.
